Zheng Quan Shi Bao Wang·2026-01-26 09:25Group 1 - The biovaccine sector saw an increase of 2.98%, ranking 9th among concept sectors, with 45 stocks rising, including Hualan Vaccine and Jindike, which hit the 20% limit up [1] - Leading stocks in the biovaccine sector included Zhifei Biological, Dongfang Biological, and CanSino, which rose by 14.87%, 12.36%, and 11.67% respectively [1] - The sector experienced a net inflow of 1.305 billion yuan from main funds, with 36 stocks receiving net inflows, and five stocks exceeding 100 million yuan in net inflow [2] Group 2 - The top net inflow stock was Watson Bio, with a net inflow of 297 million yuan, followed by Zhifei Biological, Junshi Biological, and Hualan Vaccine with net inflows of 261 million yuan, 169 million yuan, and 143 million yuan respectively [2] - The net inflow ratios for Hualan Vaccine, Junshi Biological, and Keqian Biological were 23.86%, 15.20%, and 14.32% respectively, indicating strong investor interest [3] - The biovaccine sector's performance was contrasted by declines in other sectors, such as military information technology and commercial aerospace, which fell by 4.70% and 3.56% respectively [2]